Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim results for six months ended 30 June 2018

11 Sep 2018 07:00

RNS Number : 3322A
Silence Therapeutics PLC
11 September 2018
 

 

Interim results for the six months ended 30 June 2018

 

11 September 2018

 

Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases, announces its unaudited interim results for the half year to 30 June 2018.

 

Highlights

· New leadership in place with the recruitment in July of Dr David Horn Solomon as Chief Executive Officer, an experienced public company biotech CEO, board member and biotech investor.

· The field is advancing: Gene-silencing as a therapeutic modality was granted its first drug approval by the FDA on 10 August for patisiran, validating RNAi as a class of drugs that now have a clear path to market. 

· Positive regulatory feedback and promising data in clinically validated animal disease models representative of iron overload disorders, increases confidence in Silence's lead candidate SLN124, with the first patient entered into a Phase Ib study anticipated in H2 2019. 

· Out-licenced programme, QPI-1002 for Prevention of Acute Kidney Injury progressed to Phase III clinical trial by partner Quark Pharmaceuticals, Inc.

· patisiran remains accused of infringement of Silence's Intellectual Property in the United Kingdom and Portugal.

 

Financial Highlights

· Loss after tax of £8.7 million (2017 H1: £5.5 million), reflecting increasing costs associated with the progression of lead programmes SLN124 and SLN226 towards the clinic.

· Cash and cash equivalents and term deposits of £34.3 million (FY 2017 £42.7 million).

· Net cash outflow from operating activities £8.8 million (H1 2017: £4.4 million).

 

Post Half-Year Events

· Departure of Dr Annalisa Jenkins as Chair on 19 August 2018, having upgraded Silence's R&D operations and successfully reshaped the Company's strategy, with appointment of Dr Andy Richards, CBE, as Interim Chair.

· Completion of new management review of clinical timelines results in first patient dosing for SLN124 now expected in H2 2019.

 

Dr David Horn Solomon, Chief Executive Officer of Silence Therapeutics, commented:

"The RNAi space is maturing with the first marketing approval of patisiran from Alnylam. I am excited for the opportunity to build Silence into a leading drug development company in this cutting-edge field of technology. Since joining Silence, I have been impressed by the calibre of our scientists and developers, our growing pipeline, our innovative technology platform and the commercial opportunities that these present." 

 

 

"In the coming months, we will apply for Orphan Drug designation for our clinically validated lead medicine candidate, SLN124, for the treatment of Beta-Thalassemia, in order to expedite progress towards a Phase Ib trial planned to begin in H2 2019. Whilst also advancing the development of our other pipeline of product candidates, we are targeting validating Business Development deals and continue to explore a range of financing options."

 

Dr Andy Richards, CBE, Interim Chair of Silence Therapeutics, commented:

"This has been a transformational period for Silence, with the recent recruitment of Dr David Horn Solomon as CEO, who brings extensive biotech industry leadership experience with an international track record of successful pipeline delivery, financing and deal making. At the Board level, we have also been delighted to welcome Dave Lemus who brings further expertise in commercialisation and strategic partnerships, as well as financing and transactions, especially in the US. I will serve as Interim Chair to ensure a smooth transition period to a new Chair, following the successful completion of the changes that have provided Silence with such a clear and well-directed strategy."

 

Enquiries:

 

Silence Therapeutics plc

Dr David Horn Solomon, Chief Executive Officer

Dr Andy Richards, CBE, Interim Chair

David Ellam, Chief Financial Officer

 

Tel: +44 (0) 20 3457 6900

Peel Hunt LLP (Nominated Adviser and Broker)

James Steel/ Oliver Jackson

 

Tel: +44 (0) 20 7418 8900

European IR

Consilium Strategic Communications

Mary-Jane Elliot/ Angela Gray

silencetherapeutics@consilium-comms.com

 

Tel: +44 (0) 20 3709 5700

US IR

Burns McClellan

Lisa Burns, John Grimaldi, Jill Steier

Silence.Therapeutics@burnsmc.com

Tel: +1 (212) 213 0006

 

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using its enabling delivery systems, it has achieved an additional level of specificity by delivering its therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. For more information, please visit: https://www.silence-therapeutics.com/ 

Chief Executive's Report

 

Overview

The FDA approval of patisiran demonstrates that, after 20 years of development, the RNAi class of medicines is a now a therapeutic reality. Silence has a renewed vision with new leadership, new management and a focussed strategy to pursue our development opportunities. With a broad and growing pipeline of candidate medicines in a number of therapeutic areas and a robust financial position, the company is well-positioned to grow and to maximise the potential of its GalNAc-based siRNA platform.

 

Management and Board alignment

Important appointments have been made recently, strengthening and aligning the senior management and Board of Silence. In June, Ali Mortazavi stepped down as CEO having served the company for six years. Newly appointed CEO, Dr David Horn Solomon, formerly served as CEO of Zealand Pharma A/S from 2008 to 2015. Under David's leadership the company went public on NASDAQ and its lead product, Adlyxin®, a GLP-1 receptor agonist for the treatment of type II diabetes, was approved in the US and globally and is now marketed by Sanofi as a monotherapy and in combination with Lantus® as Soliqua®. Having held senior management roles in both the US and Europe, David brings extensive international leadership experience in the biotech industry with a track record of successful pipeline delivery, financing and deal making.

 

Dave Lemus joined the Board of Directors in June as Non-Executive Director, bringing a track record and proven leadership in building and managing high performance management teams. In August, Dr Annalisa Jenkins left her role as Chair, with Dr Andy Richards assuming the role of non-executive Chair in an interim capacity to ensure a smooth transition.  In June, the appointment of Richard Jenkins as Head of Clinical Development was also announced. Richard has over 28 years' experience in clinical development and drug discovery and will be heading the clinical development function as Silence advances its lead asset through the clinic.

 

Pipeline

RNAi is now an approved class of medicines, and Silence's two lead programmes, SLN124 and SLN226, both have robust animal model data supporting progression to clinical trials in H2 2019 and 2020, respectively. Management remains fully committed to progressing these candidates to the clinic.  Following the submission of the SLN124 Briefing Document to the UK Medicines and Healthcare products Regulatory Agency, positive feedback was received at the June Scientific Advice Meeting. The first in-human study for SLN124, for the treatment of patients with Beta-Thalassemia and Myelodysplastic Syndrome, will be a Phase Ib trial. Silence will examine a variety of end points suggested by animal models as markers of efficacy to inform the clinical trial approach, and in order to seek the best possible results for patients and their caregivers.

 

Silence is pursuing additional therapeutic opportunities selected in a risk-diversified manner, focusing on indications with high unmet need where the Company's therapies can make a dramatic difference to patients. To this end, four new indications were added to the pipeline in H1 2018, including for the treatment of rare renal and rare metabolic conditions. Silence will continue to develop treatments both for rare and non-rare conditions, periodically assessing options and seeking strategic partnerships for the larger markets.

 

External partnerships

Silence's foundational IP has already been validated through out-licensing to Quark Pharmaceuticals, Inc ("Quark"), and future licensing agreements are anticipated. In July 2018, Quark announced the first patient dosed in the phase III clinical trial of QPI-1002 for prevention of Acute Kidney Injury (AKI) following cardiac surgery. The product is exclusively partnered with Novartis, who have an option for worldwide development and commercialisation in AKI. Novartis also has an option on QPI-1002 in Delayed Graft Function for which a Phase III study is ongoing, with Quark stating that first interpretative results are expected in Q4 2018.

 

Strong Intellectual Property

Technology innovation is key to remaining at the forefront of disruptive new treatment modalities such as RNAi, and this is underpinned by intellectual property (IP). In recent years GalNAc conjugates have become the main accepted and clinically validated technology for optimised stability, delivery, targeting, specificity and efficacy of RNAi.

 

In 2018, Silence continued to strengthen its overall patent estate, and protection of its GalNAc siRNA IP in particular, by filing additional patent applications for several lead sequences, several linker chemistries, multiple RNAi constructs and rules for chemical modification. Silence believes that several granted patent claims protecting its proprietary chemical modification technology are relevant to third-party RNAi medicines and that, more generally, its foundational IP underpins the RNAi field. As part of Silence's determination to enforce its patent estate against potential infringers, litigation in the UK and Portugal is ongoing against Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) ("Alnylam"). The UK litigation is proceeding towards a trial in the High Court in London beginning on, or around, 10 December 2018. While Silence continues to develop further innovation and to protect its rights and inventions, the Company remains focused on executing its core business of drug discovery and development to continue to build its therapeutic pipeline.

 

Outlook

With the management team led by Dr David Horn Solomon, complemented by a supportive and highly experienced Board, Silence has a closely aligned leadership team well-equipped to grow the Company. Silence has a strong cash position to drive the value of its platform technology and therapeutic portfolio and continues to explore a range of financing options.

 

 

Our programmes

 

A core focus is the development of our proprietary clinical-stage RNA therapeutics, having developed a broad pipeline of product candidates in a number of therapeutic areas.

 

 

SLN124

· SLN124 represents a highly promising therapeutic candidate medicine for patients with iron overload disorders, such as Beta-Thalassemia and Myelodysplastic syndrome (MDS)

 

· Positive feedback received from June Scientific Advice meeting with the UK MHRA, following the submission of the SLN124 Briefing Document

 

· Orphan designation application to be filed for Beta-Thalassemia in H2 2018

 

· Clinical development is progressing SLN124 towards a CTA filing for a First in Human study for both Beta-Thalassemia and MDS indications, with the first patient entered into the Phase Ib study anticipated in H2 2019

 

SLN226

· SLN226 has the potential to aid abstinence in alcohol dependent patients. With its unique mode of action, it provides a significantly improved therapeutic option due to its high target specificity and long duration of action

 

· Currently in preclinical development with plans to enter clinical development in 2020

 

Other indications

· Four new target indications added to the pipeline in H1 2018

 

· Pre-clinical models of cardiovascular disease efficacy scheduled for H2 2018

 

Out-licensed programmes

 

We have out-licensed our siRNA stabilisation chemistry technology (AtuRNAi™) to Quark Pharmaceuticals, who are progressing two drug candidates using this technology in late-stage clinical trials.

 

Delayed Graft Function

· The Quark drug received Orphan Drug Designation from the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) and Fast Track designation by the FDA for the DGF indication

 

· Quark completed dosing of 594 patients in a Phase III study for delayed graft function (DGF) following kidney transplantation in January 2018, with first interpretative results anticipated in Q4 2018

 

Acute Kidney Injury

· On 9th July, Quark Pharmaceuticals, Inc announced its first patient dosed in the Phase III clinical trial of QPI-1002 for prevention of Acute Kidney Injury (AKI) following cardiac surgery

 

· The Phase III study will enrol approximately 1,038 subjects at high risk for AKI following cardiac surgery at 115 sites globally

 

Silence is eligible to receive 1.5%-4% royalties from Quark plus milestones, or 15% royalties on the clinical, regulatory and commercial milestone payments and royalties received by Quark from its partner Novartis. 

Financial review

 

Operating expenses

Research & Development Expenses

Research and development expenses increased by £1.4 million to £5.2 million for H1 2018 (H1 2017:

£3.8 million). Contract Research Organisation and R&D consulting costs increased by £2.1 million to £2.9 million for H1 2018 (H1 2017: £0.8 million), reflecting increasing costs associated with the progression of lead programmes SLN124 and SLN226 towards CTA filings. This increase was offset by payroll related costs, which decreased by £0.6 million to £1.0 million in H1 2018 (H1 2017: £1.6 million), driven mainly by headcount reduction in H1 2017. Material costs remained steady at £0.4 million in H1 2018 (H1 2017: £0.4 million).

 

General and Administration Expenses

General and administration expenses increased by £1.7 million to £4.7 million for H1 2018 (H1 2017: £3.0 million). Payroll related costs increased by £0.2 million to £2.1 million in H1 2018 (H1 2017: £1.9 million) following investment in key permanent hires. Legal fees increased by £1.2 million to £1.5 million (H1 2017: £0.3 million), reflecting our commitment to defending our IP and securing the appropriate value from this IP.

 

Disposal of available-for-sale financial assets

In January 2018, the Company announced the disposal of the final tranche of Arrowhead Pharmaceuticals shares with cumulative proceeds of $24.7 million. The gain realised on disposal of these available-for-sale financial assets in H1 2018 is £0.2 million (H1 2017: nil; Full Year 2017 £9.1 million).

 

Cash flows

The Group continues to maintain a strong cash position, with cash and cash equivalents and term deposits at 30 June 2018 of £34.3 million (30 June 2017: £29.8 million; 31 December 2017: £42.7 million). The net decrease in cash and cash equivalents, including the effect of exchange rate fluctuations on cash held, was £13.4 million for H1 2018. Of this, £5.0 million was invested in a term deposit with an original maturity date of 6 months.

 

Taxation

During H1 2018 we recognised a £1.1 million current tax asset in respect of R&D tax credits (H1 2017: £1.1 million). Additionally, an estimated £1.8 million is receivable relating to 2017 R&D expenditure.

 

Principal risks and uncertainties

The principal risks and uncertainties facing the Group are set out in the 2017 Annual Report which is available on our website, www.silence-therapeutics.com. The Board does not believe that the risks and uncertainties set out in that Annual Report have changed.

 

 

 

 

 

 

Consolidated income statement - unaudited

 

 

6 months ended

Year ended

 

30 June 2018

30 June 2017

31 December 2017

 

£000s

£000s

£000s

Revenue

-

16

16

Research and development costs

(5,212)

(3,817)

(7,943)

General & administration expenses

(4,681)

(3,021)

(6,464)

Operating loss

(9,893)

(6,822)

(14,391)

Realised gain on disposals of available-for-sale financial assets

163

-

9,066

Reclassification of foreign exchange gains on liquidation of overseas subsidiary

-

-

1,344

Finance and other (expenses) / income

(57)

166

206

Loss for the period before taxation

(9,787)

(6,656)

(3,775)

Taxation

1,100

1,140

2,157

Loss for the period after taxation

(8,687)

(5,516)

(1,618)

Loss per ordinary share (basic and diluted)

(12.4p)

(7.9p)

(2.3p)

Consolidated statement of comprehensive income - unaudited

 

6 months ended

Year ended

 

30 June 2018

30 June 2017

31 December 2017

 

£000s

£000s

£000s

Loss for the period after taxation

(8,687)

(5,516)

(1,618)

Other comprehensive expense, net of tax - Items that may subsequently be reclassified to profit & loss:

 

 

 

Foreign exchange differences arising on consolidation of foreign operations

(25)

320

404

Reclassification of foreign exchange gains on liquidation of overseas subsidiary

-

-

(1,344)

Fair value movements on available-for-sale financial assets

-

(783)

9,104

Reclassification of fair value movements on disposal of available-for-sale financial assets

(156)

-

(9,066)

Total other comprehensive (expense)/income for the period

(181)

(463)

(902)

Total comprehensive expense for the period

(8,868)

(5,979)

(2,520)

 

 

 

 

Consolidated balance sheet - unaudited

 

30 June 2018

30 June 2017

31 December 2017

 

£000s

£000s

£000s

Non‑current assets

 

 

 

Property, plant and equipment

982

1,346

1,170

Goodwill

8,009

7,944

8,029

Other intangible assets

18

37

28

Available-for-sale financial assets

-

8,555

-

Other receivables

233

233

233

 

9,242

18,115

9,460

Current assets

 

 

 

Trade and other receivables

1,136

601

733

R&D tax credit receivable

2,850

2,740

1,750

Investments held for sale

-

3

-

Available-for-sale financial assets

-

-

319

Six-month term deposit

5,000

-

-

Cash and cash equivalents

29,336

29,849

42,745

 

38,322

33,193

45,547

Current liabilities

 

 

 

Trade and other payables

(3,603)

(2,768)

(2,657)

Total assets less current liabilities

43,961

48,540

52,350

Net assets

43,961

48,540

52,350

Capital and reserves attributable to the owners of the parent

 

 

 

Share capital

3,504

3,499

3,500

Capital reserves

163,517

163,751

163,215

Translation reserve

2,038

3,323

2,063

Retained loss

(125,098)

(122,033)

(116,428)

Total equity

43,961

48,540

52,350

 

 

 

 

 

Consolidated statement of changes in equity - unaudited

 

six months ended 30 June 2018

 

 

 

 

 

 

 

Share

Capital

Capital Reserves

Translation Reserve

Accumulated Losses

 Total

 

£000s

£000s

£000s

£000s

£000s

At 1 January 2018

3,500

163,215

2,063

(116,428)

52,350

Recognition of share-based payments

-

388

-

-

388

Lapse of vested options in period

-

(128)

-

128

-

Options exercised in the period

-

(45)

-

45

-

Proceeds from shares issued

4

87

-

-

91

Transactions with owners recognised directly in equity

4

302

-

173

479

Loss for six months

-

-

-

(8,687)

(8,687)

Other comprehensive income

 

 

 

 

 

Exchange differences arising on consolidation of foreign operations

-

-

(25)

-

(25)

Reclassification of fair value movements on disposal of available-for-sale financial assets

-

-

-

(156)

(156)

Total comprehensive expense for the period

-

-

(25)

(8,843)

(8,868)

At 30 June 2018

3,504

163,517

2,038

(125,098)

43,961

 

 

 

 

 

 

year ended 31 December 2017

 

 

 

 

 

 

Share

Capital

Capital Reserves

Translation Reserve

Accumulated Losses

 Total

 

£000s

£000s

£000s

£000s

£000s

At 1 January 2017

3,490

163,641

3,003

(115,950)

54,184

Recognition of share-based payments

-

638

-

-

638

Lapse of vested options in period

-

(1,015)

-

1,015

-

Options exercised in the period

-

(87)

-

87

-

Proceeds from shares issues

10

38

-

-

48

Transactions with owners recognised directly in equity

10

 (426)

-

1,102

686

Loss for year

-

-

 

(1,618)

(1,618)

Other comprehensive income

 

 

 

 

 

Exchange differences arising on consolidation of foreign operations

-

-

404

-

404

Reclassification of foreign exchange gains on liquidation of overseas subsidiary

-

-

(1,344)

-

(1,344)

Fair value movements on available-for-sale financial assets

-

-

-

9,104

9,104

Reclassification of fair value movements on disposal of available-for-sale financial assets

-

-

-

(9,066)

(9,066)

Total comprehensive expense for the year

-

-

(940)

(1,580)

(2,520)

At 31 December 2017

3,500

163,215

2,063

(116,428)

52,350

         

 

 

 

 

Consolidated cash flow statement - unaudited

 

 

6 months ended

Year ended

 

30 June 2018

30 June 2017

31 December 2017

 

£000s

£000s

£000s

Cash flow from operating activities

 

 

 

Loss before tax

(9,787)

(6,656)

(3,775)

Depreciation charges

185

189

414

Amortisation charges

8

9

19

Charge for the period in respect of share-based payments

388

288

638

Realised gain on disposal of available-for-sale financial assets

(163)

-

(9,066)

Reclassification of foreign exchange gains on liquidation of overseas subsidiary

-

-

(1,344)

Finance and other expense/(income)

57

(166)

(206)

Impairment of investment

-

-

3

(Increase)/Decrease in trade and other receivables

(403)

796

664

Increase in trade and other payables

946

1,158

1,047

Cash spent on operations

(8,769)

(4,382)

(11,606)

Corporation tax credits received

-

-

2,007

Net cash outflow from operating activities

(8,769)

(4,382)

(9,599)

Cash flow from investing activities

 

 

 

Acquisition of financial assets available for sale

-

(4,921)

(4,921)

Disposal of financial assets available for sale

320

-

18,123

Purchase of six-month term deposit

(5,000)

 

 

Interest received/(paid)

4

4

(15)

Purchase of property, plant and equipment

-

(118)

(173)

Net cash (outflow)/inflow from investing activities

(4,676)

(5,035)

13,014

Cash flow from financing activities

 

 

 

Proceeds from issue of share capital

91

48

48

Net cash inflow/(outflow) from financing activities

91

48

48

(Decrease)/increase in cash and cash equivalents

(13,354)

(9,369)

3,463

Cash and cash equivalent at start of period

42,745

39,012

39,012

Net decrease in the period

(13,354)

(9,369)

3,463

Effect of exchange rate fluctuations on cash held

(55)

206

270

Cash and cash equivalent at end of period

29,336

29,849

42,745

 

 

 

 

Notes to the financial statements

six months ended 30 June 2018

 

1. Basis of Preparation and Accounting Policies

 

These condensed consolidated interim financial statements for the six months ended 30 June 2018 have been prepared in accordance with IAS 34 - 'Interim Financial Reporting' as adopted by the European Union. The accounting policies adopted are consistent with those of the financial statements for the year ended 31 December 2017.

 

This condensed consolidated interim financial information has been neither reviewed nor audited. The interim financial statements do not comprise statutory accounts within the meaning of Section 434 of the Companies Act 2006. The comparative figures for the six months ended 30 June 2017 are not the Company's statutory accounts for that financial period. The 2017 full year accounts have been reported on by the Company's auditors and delivered to the Registrar of companies. The report of the auditors was unqualified and did not contain a statement under section 498(2) or (3) of the Companies Act 2006.

 

IFRS 15 was implemented by the Group on 1 January 2018. This has not had a material impact for the Group.

 

IFRS 9 was implemented by the Group on 1 January 2018. This has not had a material impact on the accounting for financial instruments held by the Group.

 

2. Going concern

 

The financial statements have been prepared on a going concern basis that assumes that the Company will continue in operational existence for the foreseeable future.

 

During the period, the Company met its day-to-day working capital requirements through existing cash resources. The Company had a net decrease in the cash and cash equivalent in the period ended 30 June 2018 of £13.4 million and at 30 June 2018 had cash balances of £29.3 million plus a six-month term deposit of £5.0 million. The Directors have reviewed the working capital requirements of the Company for the next 12 months from the date of the approval of these interim financial statements and are confident that these can be met.

 

 

 

3. Segment reporting

 

In the six months ended 30 June 2018, the Group operated in the specific technology field of RNA therapeutics.

 

Business segments

The Group has identified the Chief Executive Officer as the Chief Operating Decision Maker ("CODM"). The CODM determined the Group had one business segment, the development of RNAi based medicines. This is in line with reporting to the Executive Committee and senior management. The information used internally by the CODM is the same as that disclosed in the Financial Statements.

 

Non‑current assets

UK£000s

Germany£000s

Total

£000s

 

As at 30 June 2018

550

8,692

9,242

 

As at 30 June 2017

9,200

8,915

18,115

 

As at 31 December 2017

611

8,849

9,460

 

 

 

6 months ended

Year ended

Revenue Analysis

30 June 2018

30 June 2017

31 December 2017

£000s

£000s

£000s

Research collaboration

-

16

16

        

 

The country of registration of the single fee-paying party is the USA. The revenue was billed and received in US Dollars.

 

4. Loss per share

 

The loss per share is based on the loss for the period after taxation attributable to equity holders of £8.69 million (year ended 31 December 2017 - loss £1.62 million; six months ended 30 June 2017 - loss £5.52 million) and on the weighted average of 70,033,448 ordinary shares in issue during the period (year ended 31 December 2017 - 69,924,558; six months ended 30 June 2017 - 69,876,568).

 

The options outstanding at 30 June 2018, 31 December 2017 and 30 June 2017 are considered to be non-dilutive in that their conversion into ordinary shares would decrease the net loss per share. Consequently, there is no diluted loss per share to report for the periods reported.

 

5. Taxation

A £1.10 million current tax asset was recognised in respect of research and development tax credits in the six months ended 30 June 2018 (six months ended 30 June 2017: £1.14 million).

 

6. Related party transactions

 

Transactions between the Company and its subsidiaries, which are related parties, have been eliminated on consolidation and are not disclosed in this note. There are no other related party transactions which would require disclosure.

 

 

A PDF version of this announcement including pipeline graphics can be found here:

http://www.rns-pdf.londonstockexchange.com/rns/3322A_1-2018-9-10.pdf

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
IR EAKNEFLDPEFF
Date   Source Headline
26th Nov 20217:00 amRNSUpdate on AIM Delisting
25th Nov 20215:30 pmRNSSilence Therapeutics
16th Nov 20217:00 amRNSThird Quarter 2021 Financial Results
11th Nov 20217:00 amRNSSilence to Present at Jefferies London Conference
10th Nov 20217:00 amRNSHolding(s) in Company
5th Nov 20217:00 amRNSNew Key Shareholder
1st Nov 20215:33 pmRNSResult of General Meeting
1st Nov 20214:49 pmRNSTotal Voting Rights
28th Oct 20214:02 pmRNSHolding(s) in Company
21st Oct 20211:30 pmRNSSilence Provides Pipeline Updates at 2021 R&D Day
15th Oct 20217:05 amRNSProposed Cancellation of Trading on AIM
15th Oct 20217:00 amRNSSilence and Hansoh Pharma Announce Collaboration
8th Oct 20217:00 amRNSBlock Listing Return
8th Oct 20217:00 amRNSTotal Voting Rights
7th Oct 20217:00 amRNSSilence Therapeutics to host R&D day
28th Sep 20217:00 amRNSChardan Genetic Medicines Conference Participation
8th Sep 20214:03 pmRNSHolding(s) in Company
8th Sep 20214:00 pmRNSHolding(s) in Company
1st Sep 20217:00 amRNSSilence Appoints Senior VP of BD, AM and NPD.
25th Aug 20217:00 amRNSSilence to Participate in Investor Conferences
12th Aug 20217:00 amRNSSilence Therapeutics Report Half-Year 2021 Results
6th Aug 202112:15 pmRNSHolding(s) in Company
6th Aug 202112:13 pmRNSHolding(s) in Company
5th Aug 20212:57 pmRNSTotal Voting Rights
15th Jul 20217:00 amRNSNotice of half year results
15th Jun 20215:54 pmRNSResults of Annual General Meeting
7th Jun 20217:00 amRNSSilence to present SL124 data at EHA
25th May 20217:00 amRNS$40m Payment from AstraZeneca for Collaboration
19th May 20217:00 amRNSPhase 1 Study in Healthy Volunteers Positive Data
12th May 20217:00 amRNSSilence attends RBC Global Healthcare Conference
7th May 20217:00 amRNSNotice of AGM
4th May 20217:00 amRNSSilence Support International Thalassemia Day
30th Apr 20214:12 pmRNSHolding(s) in Company
29th Apr 20215:58 pmRNSHolding(s) in Company
29th Apr 20217:00 amRNSFirst patient dosed in GEMINI II
28th Apr 20217:00 amRNSSilence Achieves Research Milestone Payment
27th Apr 20217:00 amRNSGrant of Employee Options
19th Apr 20217:00 amRNSPurchase of ADS and PDMR Shareholding
15th Apr 20217:00 amRNSPublication in Cardiovascular Research
7th Apr 20217:00 amRNSSilence to Present at Virtual Needham Conference
30th Mar 20216:13 pmRNSSilence Therapeutics Publication of Annual Report
30th Mar 20219:04 amRNSREPLACEMENT Silence Reports Full-year 2020 Results
30th Mar 20217:00 amRNSSilence Reports Full-year 2020 Results
26th Mar 20217:00 amRNSBlock Listing Application
4th Mar 20217:29 amRNSSilence presents at Barclays Healthcare Conference
1st Mar 20217:00 amRNSNotice of Annual Results
26th Feb 20217:00 amRNSSilence & Mallinckrodt Initiate Work on 3rd Target
24th Feb 20213:09 pmRNSHolding(s) in Company
22nd Feb 20217:00 amRNSSilence to Partake in March Investor Conferences
18th Feb 20217:00 amRNSSilence to present at SVB Leerink Conference

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.